Pharmacotherapy of Diabetes: New Developments: Improving Life and Prognosis for Diabetic Patients by Carl Erik MogensenPharmacotherapy of Diabetes: New Developments: Improving Life and Prognosis for Diabetic Patients by Carl Erik Mogensen

Pharmacotherapy of Diabetes: New Developments: Improving Life and Prognosis for Diabetic Patients

EditorCarl Erik Mogensen

Paperback | November 4, 2010

Pricing and Purchase Info

$249.11 online 
$258.95 list price
Earn 1246 plum® points
Quantity:

In stock online

Ships free on orders over $25

Not available in stores

about

Diabetes is a huge and growing healthcare worry, especially in Western countries. The treatment of both types - 1 and 2 - of this disease has changed radically over the past few years. This work provides an overview of all the changes that will come to be implemented in clinical practice. Summarizing all aspects of treatment, this book delineates the large amount of research work that has been completed over the last few years into the relief of complications in diabetes and vascular medicine in general.
Title:Pharmacotherapy of Diabetes: New Developments: Improving Life and Prognosis for Diabetic PatientsFormat:PaperbackDimensions:299 pages, 10 × 7.01 × 0.03 inPublished:November 4, 2010Publisher:Springer USLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:1441943455

ISBN - 13:9781441943453

Look for similar items by category:

Reviews

Table of Contents

Foreword.- Section: Overview.- Can we defeat the diabetic epidemic? Defining the world problem.- Diabetogenic, drugs, and medications with adverse metabolic effects.- New definitions of diabetes: consequences.- Milestones from the past and common misunderstandings.- Section: Pharmacotherapy of Diabetes.- Treatment of the metabolic syndrome today and tomorrow.- Treatment of diabetic catastrophes.- Insulin and new insulin analogues: inhaled insulin and insulin pumps in Type 1 diabetes.- Insulin and new insulin analogues in Type 2 diabetes.- New drugs and developments: pipeline drugs.- The increasing role of sulfonylurea, repaglinide and metformin.- The glitazones, lessons so far.- The incretin modulators.- Glycosylation inhibitors, PKC inhibitors and related interventions against complications.- The role of acarbose.- Multifactorial intervention in T2 diabetes.- Clinical trials in progress.- Section: Treating the Comorbid Patient.- Obesity and pharmacological treatment.- Lipid lowering.- Diabetes and cardiovascular disease.- Cardiology drugs for diabetic patients.- Aspirin and platelet active drugs.- ACE-Is and ARBs and blood pressure lowering, including effect on renal disease.- Section: Diabetic Complications.- Treatment of erectile and sexual dysfunction.- Stroke, diabetes, and glucose metabolism.- Foot ulcers.- Diabetic neuropathy.- Pregnancy - pharmacological problems.- Diabetic eye care.- Section: Guidelines.- Notes from drug agencies, professional organizations and pharmaeconomics.